We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections
We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
Updated: 12/31/1969
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Updated: 12/31/1969
A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics
Status: Enrolling
Updated: 12/31/1969
Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Updated: 12/31/1969
A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Updated: 12/31/1969
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2 up to and Including 13 Years of Age
Status: Enrolling
Updated: 12/31/1969
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Updated: 12/31/1969
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2 up to and Including 13 Years of Age
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Updated: 12/31/1969
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2 up to and Including 13 Years of Age
Status: Enrolling
Updated: 12/31/1969
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Updated: 12/31/1969
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2 up to and Including 13 Years of Age
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Case Series of Weekly Applications of dHACM in Treatment of Pressure Ulcers
Updated: 12/31/1969
A Case Series to Investigate the Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane (dHACM) in the Treatment of Pressure Ulcers
Status: Enrolling
Updated: 12/31/1969
Case Series of Weekly Applications of dHACM in Treatment of Pressure Ulcers
Updated: 12/31/1969
A Case Series to Investigate the Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane (dHACM) in the Treatment of Pressure Ulcers
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
AFT/CLP-LAL RCT Stage 3 or 4 Pressure Injuries
Updated: 12/31/1969
A Randomized Controlled Pilot Study Comparing Air Fluidized Therapy (AFT) to a Continuous Low Pressure (CLP) Low Air Loss (LAL) Support Surface in the Treatment of Stage 3 or 4 Pressure Injuries
Status: Enrolling
Updated: 12/31/1969
AFT/CLP-LAL RCT Stage 3 or 4 Pressure Injuries
Updated: 12/31/1969
A Randomized Controlled Pilot Study Comparing Air Fluidized Therapy (AFT) to a Continuous Low Pressure (CLP) Low Air Loss (LAL) Support Surface in the Treatment of Stage 3 or 4 Pressure Injuries
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
AFT/CLP-LAL RCT Stage 3 or 4 Pressure Injuries
Updated: 12/31/1969
A Randomized Controlled Pilot Study Comparing Air Fluidized Therapy (AFT) to a Continuous Low Pressure (CLP) Low Air Loss (LAL) Support Surface in the Treatment of Stage 3 or 4 Pressure Injuries
Status: Enrolling
Updated: 12/31/1969
AFT/CLP-LAL RCT Stage 3 or 4 Pressure Injuries
Updated: 12/31/1969
A Randomized Controlled Pilot Study Comparing Air Fluidized Therapy (AFT) to a Continuous Low Pressure (CLP) Low Air Loss (LAL) Support Surface in the Treatment of Stage 3 or 4 Pressure Injuries
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
The RESPOND Registry
Updated: 12/31/1969
Real-World Effectiveness Study of PuraPly™ AM on Wounds
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Updated: 12/31/1969
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials